anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
FIELD: medicine. SUBSTANCE: method involves determining patient chakras related to pathologically changed organs colors corresponding to them. Favorable day is selected by means of special calendar to introduce per os autonomous electric stimulation device. Diet is administered 5-7 days before the autonomous electric stimulation device is introduced and sorbent agents and phytopreparations are also taken. Every day the autonomous electric stimulation device is to be placed on or under the tongue 3 times a day during 20-30 min and color therapy is carried out. Exposure to one or two of basic colors (red, yellow or blue) is carried out depending on the chakra color in the morning. The color corresponding to the chakra is applied in the evening time. Household articles and foodstuff products of the corresponding colors are additionally used. The autonomous electric stimulation device is introduced per os at 4-6 o'clock before afternoon on the empty stomach in standing position being the initial position from which the patient is transferred into a lying position first on the left side, on the right side and on the back. When lying on the right side, the patient drinks mineral water. EFFECT: enhanced effectiveness of treatment; prevented adverse side effects; improved general health state of patients. 5 cl, 2 dwg
The invention relates to a Chinese patent medicine and a traditional Chinese medicine decoction used for treating hemoptysis caused by bronchiectasis. The invention relates to the fields of biology and medicine. The Chinese patent medicine and the traditional Chinese medicine decoction are characterized in that: the medicine and the decoction are prepared by using five traditional Chinese medicines. The medicine and the decoction provided by the invention are advantaged in that: the traditional Chinese medicine formula used for treating hemoptysis caused by bronchiectasis is a prescription of a famous traditional Chinese medical doctor in an institute of traditional Chinese medicine. It is proofed that, the traditional Chinese medicine decoction has a good curative effect against hemoptysis caused by bronchiectasis. The traditional Chinese medicine prescription can be developed into Chinese patent medicine pills, powders, granules, tablets, capsules, and the like. Therefore, the advantages of the Chinese patent medicine can be developed, the medicine is ready to be used, and the medicine can be used in emergencies. The medicine is convenient to store and to carry. The development of the traditional Chinese medicine decoction and the Chinese patent medicine has great prospects for commercial development.
The present invention relates to a kind of extraction processes of mulberrin crude product, belong to sun-prevention component extractive technique field.A kind of extraction process of mulberrin crude product, includes the following steps：1. crushing；2. degreasing；3. weighing；4. Microwave Extraction；5. detaching drying；A kind of includes the sun-screening agent of mulberrin, includes 1 15 parts of mulberrin intermediate, 3 parts of lecithin, 1 part of carbomer, 1 part of carbomer neutralizer and water according to mass fraction；The mulberrin intermediate is the mixture of mulberrin, lipid solvent and antioxidant.A kind of more general microwave extraction method of extraction process extraction rate of mulberrin crude product of the present invention faster, extraction efficiency higher；Include mulberrin sun-screening agent is of low cost, sun-proof result is good.
Endotracheal tubes with subglottic secretion drainage (incorporating a suction port above the cuff) have been shown to reduce the incidence of ventilator-associated pneumonia. Subglottic secretion drainage can be either continuous or intermittent. However, concerns about the safety of continuous subglottic secretion drainage were raised in an experimental study in sheep, which found widespread injuries to tracheal mucosa and/or submucosa. Our objective is therefore to compare intermittent versus continuous subglottic secretion drainage on tracheal mucosa damages in patients requiring mechanical ventilation for an expected duration of more than 24 hours. Tracheal mucosa injuries will be assessed by tracheal fibroscopy. Secondary endpoints are the volume of daily secretions suctioned, the occurrence of difficulties or impossibilities of secretion drainage, and the occurrence of ventilator-associated pneumonia.
Schizophrenia is a chronic, debilitating mental illness caused by both genetic and environmental factors. Genetic factors play a major role in schizophrenia development. Early growth response 3 (EGR3) is a member of the EGR family, which is associated with schizophrenia. Accumulating studies have investigated the relationship between EGR3 and schizophrenia. However, the role of EGR3 in schizophrenia pathogenesis remains unclear. In the present review, we focus on the progress of research related to the role of EGR3 in schizophrenia, including association studies between EGR3 and schizophrenia, abnormal gene expressional analysis of EGR3 in schizophrenia, biological function studies of EGR3 in schizophrenia, the molecular regulatory mechanism of EGR3 and schizophrenia susceptibility candidate genes, and possible role of EGR3 in the immune system function in schizophrenia. In summary, EGR3 is a schizophrenia risk candidate factor and has comprehensive regulatory roles in schizophrenia pathogenesis. Further studies investigating the molecular mechanisms of EGR3 in schizophrenia are warranted for understanding the pathophysiology of this disorder as well as the development of new therapeutic strategies for the treatment and control of this disorder.
This is a longitudinal study with a randomized crossover design, double-blind, placebo-controlled, and with washout period. Thirty non-dialysis patients of both genders, aged between 18 and 60 years and with CKD stage3-4 (glomerular filtration rate \< 59 mL/min/1.73 m2) will be included in the study. Pregnant patients, smokers and those under use of antibiotics in the last 3 months, or in use antithrombotic, pre-, pro- or synbiotic supplements, antioxidant supplements or habitual cranberry intake will be excluded. In addition, those with autoimmune and infectious diseases, cancer, liver diseases and HIV will also not be included in the study. The patients that fulfill the eligible criteria and sign the ethical informed consent will be randomized to either Group A (Cranberry) or Group B (Placebo). During 12 weeks, patients allocated in group A will receive capsules containing cranberry extract (Vaccinium macrocarpon to 25% anthocyanosides 160mg, equivalent to 40mg anthocyanosides), once daily (lunch), totaling 500mg / day and those allocated in the group B will receive a placebo (500mg of corn starch). After the supplementation period, a 12-week washout will be performed for subsequent crossover of the supplement. The randomization will be computed in the ratio of 1: 1, with block size of 15 (Cranberry group and Control), to receive cranberry or placebo. This project was approved by the Ethics Committee of the Faculty of Medicine-UFF, n. 2.653.752.
The invention relates to an endoplasmic reticulum membrane fusion liposome and a preparation method and application thereof, belonging to the technical field of biology. The method comprises the following steps: (1) extracting endoplasmic reticulum membrane; (2) preparing and characterizing the liposome; (3) preparation and characterization of endoplasmic reticulum membrane fusogenic liposomes. The particle size of the liposome prepared by using a film dispersion method is controlled to be 103.03 +/-7.99 nm, the particle size distribution is narrow, PDI =0.149 +/-0.02, and the zeta potential is 41.8 +/-2.71 mV. After fusing with endoplasmic reticulum membrane, the particle size of the final endoplasmic reticulum membrane fusion liposome (EM/Lip) is controlled to be 124.27 +/-4.21 nm, PDI =0.19 +/-0.03, and zeta potential is 14.27 +/-2.50 mV. According to the invention, most of EM/Lip enters cells and is positioned in endoplasmic reticulum, and rarely enters lysosome, so that the degradation of the drug in the lysosome is avoided, and the targeting function of the endoplasmic reticulum is realized. The endoplasmic reticulum membrane fusion liposome obtained by the invention can have an endoplasmic reticulum targeting function in immune cells and tumor cells, and a laser confocal three-dimensional image technology is also well applied to the research on the distribution of a subcellular organelle level nano preparation.
PCT No. PCT/GB91/01730 Sec. 371 Date Apr. 5, 1993 Sec. 102(e) Date Apr. 5, 1993 PCT Filed Oct. 4, 1991 PCT Pub. No. WO92/05811 PCT Pub. Date Apr. 16, 1992.The invention pertains to a method of preparing a device for transdermal delivery of an active ingredient which is solid at room temperature and in which part or all of the active ingredient is present in a saturated or supersaturated solution. In the first step, a mixture is prepared which includes at least a polymer adhesive, a vehicle for the polymer adhesive, an active ingredient and a solvent mixture for the active ingredient which solvent mixture comprises at least two solvents having different boiling points. The mixture is then formed into a film and dried. The vehicle for the polymer adhesive and at least one of the solvents and the solvent mixture have boiling points below the drying temperature of the film, while at least one of the solvents in the solvent mixture has a boiling point above the drying temperature of the film. Thus, at least one of the solvents remains in the film after drying and the solubility of the active ingredient contained in the remaining solvent is greater than 10%.
Ghrelin is a relatively 'new' hormone that is produced in the stomach and to a lesser extend in the hypothalamus of the brain. The actions of ghrelin are diverse and includes stimulation of the appetite center of the brain and the release of growth hormone. We have for the first time shown that ghrelin also stimulates the metabolism of fatty acids and induces insulin resistance in skeletal muscle. These effects have we confirmed in growth hormone deficient subjects on a stabile substitution treatment with growth hormone and hydrocortisone. With these subjects we can investigate the effects of ghrelin that are independent of growth hormone. The present study is a continuation of these findings, as we wish to investigate whether the insulin resistance effect of ghrelin is dependent of the concomitant metabolism of fatty acids. This is possible by administration of the niacin acid antagonist Acipimox, that blocks the fatty acid metabolism reversibly. We have applied this experimental principle in other settings with success.

Knowledge of the effects of ghrelin in general can in shot-sight as well as in long-sight have great importance for the understanding of growth disorders from overweight and type 2 diabetes to malnutrition and eating disorders.
PROBLEM TO BE SOLVED: To obtain a skin preparation for external use having melanin generation-suppressing action, tyrosinase activity-inhibiting action, excellent effects to light-coloring and whitening, and excellent safety by mixing a specific compound derived from a specific plant. SOLUTION: A mixture of diglyceride monoacyl glycosides of formula I [R1 R3 are each one of formula II ((n) is 5 or 7)] is used as an active component of the objective preparation. The compound of the formula is obtained by extracting a plant such as Cola-de-Caballo in an organic solvent, dividing with ethyl acetate and water, and purifying the ethyl acetate phase by silica gel column chromatography, etc. A mixing amount of compound of the formula is 0.005-20.0wt.% based on whole amount of the preparation for external use. The skin preparation for external use is used as, e.g. an orintment, cream, a latex, lotion, a pack and a bathing agent, and effective for preventing and improving of chromatosis after sunburn, spot, freckle, chloasma, etc.
Partial leptin reduction can induce significant weight loss, while weight loss contributes to partial leptin reduction. The cause-and-effect relationship between leptin reduction and weight loss remains to be further elucidated. Here, we show that FGF21 and the glucagon-like peptide 1 receptor (GLP-1R) agonist liraglutide rapidly induced a reduction in leptin. This leptin reduction contributed to the beneficial effects of GLP-1R agonism in metabolic health, as transgenically maintaining leptin levels during treatment partially curtailed the beneficial effects seen with these agonists. Moreover, a higher degree of leptin reduction during treatment, induced by including a leptin neutralizing antibody with either FGF21 or liraglutide, synergistically induced greater weight loss and better glucose tolerance in diet-induced obese mice. Furthermore, upon cessation of either liraglutide or FGF21 treatment, the expected immediate weight regain was observed, associated with a rapid increase in circulating leptin levels. Prevention of this leptin surge with leptin neutralizing antibodies slowed down weight gain and preserved better glucose tolerance. Mechanistically, a significant reduction in leptin induced a higher degree of leptin sensitivity in hypothalamic neurons. Our observations support a model that postulates that a reduction of leptin levels is a necessary prerequisite for substantial weight loss, and partial leptin reduction is a viable strategy to treat obesity and its associated insulin resistance.
Chronic gingivitis patients whose mechanical plaque control was supported with 0.12% CHX. Each patient was instructed to use 15 mL of the mouthwash delivered to them for 60 seconds 30 minutes after brushing in the morning and evening for 4 weeks.
The present application discloses compositions and methods of synthesis and use of  18 F or  19 F labeled molecules of use in PET or MRI imaging. The labeled molecules may be peptides or proteins, although other types of molecules may be labeled. Preferably, the  18 F or  19 F is conjugated to a targeting molecule by formation of a metal complex and binding of the  18 F- or  19 F-metal complex to a chelating moiety. Alternatively, the metal may first be conjugated to the chelating group and subsequently the  18 F or  19 F bound to the metal. In other embodiments, the  18 F or  19 F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The  18 F or  19 F labeled targetable construct peptides are stable in serum at 37°C for a sufficient time to perform PET or MRI imaging.
Luspatercept was given once subcutaneously every 3 weeks for 24 weeks in the treatment period, . Luspatercept was started at 1·0 mg/kg with titration up to 1·25 mg/kg, or reduction in the event of toxicity or excessive haemoglobin concentration increase.. During the treatment, the hemoglobin of patients before each injection of luspatercept should be monitored, and the common adverse reactions (AE) should be monitored. According to the judgment and practice of clinicians, the best supportive treatment, including blood transfusion, iron chelation therapy, and anti-infection treatment, should be provided for patients receiving luspatercept treatment. If the patient has blood transfusion, it is necessary to obtain the blood transfusion record from the hospital system.Concomitant use of iron chelating agents was also recorded.
FIELD: veterinary science. SUBSTANCE: method involves the use of colloidal silver preparations (protargol, collargol) at dose 5-15 mg/kg body mass by enteral route. Method is used for treatment plague, parvoviral enteritis and other acute viral disease in dog, mink, fox, polar fox. Preparations were administrated 3 times per a day for 6-8 days. EFFECT: enhanced effectiveness of treatment. 2 tbl
A sprayable polymeric foam hemostat for both compressible and non-compressible (intracavitary) acute wounds is disclosed. The foam comprises hydrophobically-modified polymers, such as hm-chitosan, or other amphiphilic polymers that anchor themselves within the membrane of cells in the vicinity of the wound. By rapidly expanding upon being released from a canister pressurized with liquefied gas propellant, the foam is able to enter injured body cavities and staunch bleeding. The seal created is strong enough to substantially prevent the loss of blood from these cavities. Hydrophobically-modified polymers inherently prevent microbial infections and are suitable for oxygen transfer required during normal wound metabolism. The amphiphilic polymers form solid gel networks with blood cells to create a physical clotting mechanism that prevent loss of blood.
Patients will have BP assessed at baseline, 12-, and 24-weeks in the pharmacy by the pharmacist. Patients will not receive a home blood pressure monitor. Pharmacist will provide them usual care, education and counselling on BP management. Pharmacists will fax BP readings to the patient's prescribing clinician but will not provide any suggestions for therapy modification. After 24-weeks patients will be offered a home blood pressure monitor with education on its use. They will then be offered to crossover to the intervention group for the next 6-months or have their care returned to their prescribing clinician with no pharmacist specific interventions outside of usual pharmacy care activities and have a single follow-up at month-12 with the pharmacist reviewing home BP monitor use and reporting of data to prescribing clinician.
PURPOSE: A composition for preventing or treating Th17-mediated diseases containing poly-gamma-glutamic acid is provided to inhibit the differentiation of Th17 cells, and to promote the differentiation of Treg cells, thereby preventing and treating the Th17-mediated disease effectively. CONSTITUTION: A composition for preventing or treating Th17-mediated diseases contains containing poly-gamma-glutamic acid as an active ingredient. The molecular weight of the poly-gamma-glutamic acid is 1 to 2000 kDa. The poly-gamma-glutamic acid decreases or suppresses the differentiation of undifferentiated T cells to Th17 cells. The poly-gamma-glutamic acid increases or promotes the differentiation of undifferentiated T cells to regulatory T cells. The undifferentiated T cell is a CD4 positive T cell. [Reference numerals] (AA) Normal control group
The invention discloses a preparation method of a porous microsphere. The method mainly comprises the following step of performing electric injection by electric injection liquid containing polymers for drug carriers, a first solvent and a second solvent under the electrostatic spinning condition. The invention also provides the porous microsphere prepared by the method, and a drug carrying microsphere using the porous microsphere as a carrier. The invention also provides a preparation method of the drug carrying microsphere and the drug carrying microsphere prepared by the preparation method. The invention also provides application of the drug carrying microsphere to the preparation of medicine for treating mucosa-associated diseases. The obtained drug carrying microsphere has strong mucosa adhesion force and high slow-release effects.
It is a randomized clinical trial that will be conducted at Children Hospital PIMS, Islamabad over the period of 6 months. Sample size is calculated using World Health Organization (WHO) calculator, keeping confidence level 95%, level of significance 5%, power of the test 80%,anticipated population proportion 1: 84%, anticipated population proportion 2: 93%, which turn out to be 30.Consecutive non probability sampling technique will be used. Children 1-12 years both male and female visiting/admitted in Children Hospital PIMS with acute diarrhea of less than 15 days duration will be enrolled in the study after taking informed consent from the parents. Children requiring emergency resuscitation, having chronic diarrhea i-e more than 15 days duration, having other comorbid conditions like heart, kidney and liver failure, having metabolic disorder and who are allergic to egg or any of the contents will be excluded from the study.

Child's name, age, sex will be recorded by the on duty doctor. Patients will be randomly allocated to two equal groups. Group A (GA) will receive anti secretory 1.5mg/kg/dose three doses per oral in 24 hours along with oral rehydration, while Group B (GB) will receive a single dose of bovine colostrum and egg solids as 7 g of dry powder reconstituted in 30 mL of water and taken orally once daily for 3 days along with oral rehydration. Response to treatment will be assessed by recording the reduction in frequency of diarrheal episodes after administration of drug and duration in which the diarrheal episodes were reduced. Data will be collected through a structured proforma.

All data will be analyzed using latest SPSS version. Quantitative variables such as age, time will be presented as means and standard deviations. Qualitative variables such as age groups, sex, recurrence of seizures and efficacy will be measured as frequency and percentages. Effect modifiers like age, gender will be controlled by stratification. Post stratification chi-square test will be applied keeping p value ≤0.05 as significant.
Electrical impedance tomography is a bedside method of ventilation monitoring. The bioimpedance of the tissue depends, among other things, on its blood content. The area of the chest and especially the lungs is a heavily perfused tissue, which also serves as one of the reservoirs of blood in case of blood loss. It is therefore possible that blood loss will be visible on chest bioimpedance relatively soon.

The study will be performed on voluntary blood donors. Blood loss of 450 mL will be caused by the collection of donated blood. During blood collection at the transfusion department, thoracic bioimpedance will be measured using electrical impedance tomography. The resulting signal change will then be analyzed to determine the possibility of detecting and measuring blood loss using electrical impedance tomography.
Family-based behavioural therapy either in group or in individual setting. Parents can choose between the 2 types of therapy.
Design: We propose a randomized double blind placebo controlled study of patients with early course Schizophrenia (SZ) / schizoaffective disorder (SZA) patients exposed to HSV-1, who are receiving antipsychotic drugs. The effects of VAV augmentation or PLA as adjuncts to conventional antipsychotic drug treatment will be evaluated. As outcomes, we will evaluate clinical symptoms, cognitive variables, overall function (including social function) and side effects. The participants will be under the direct care of the Indian investigators during the study. Ratings will be performed blind by research staff. We will pre-screen for HSV-1 exposure. There will be a 2 week placebo run in phase, 16 week augmentation and 4 week follow up to identify post-treatment side effects.
The success rate of omalizumab discontinuation is 50-75.5%. However, such data are scarce in Japan. We retrospectively investigated the clinical progression following the cessation of long-term omalizumab treatment (>5 years) in severe allergic asthma patients who have achieved super-responder status, defined as being off any oral maintenance corticosteroids without experiencing exacerbations requiring systemic corticosteroids for >1 year. Six (28.6%) among 21 patients recommenced after a median period of 5.5 (4.3-12.5) months later due to exacerbated asthma control, resulting in improved asthma management for all patients. The rates of patients who successfully remained off omalizumab treatment for 1 and 2 years were 72.4% and 65.8%, respectively. Specific IgE levels after discontinuing omalizumab treatment significantly decreased compared to those at initiating this treatment in 10 patients who successfully remained off this treatment. Therefore, discontinuing omalizumab treatment may be considered for patients continuing treatment beyond 5 years and achieving super-responder status.